Is kevzara an effective treatment for polymyalgia rheumatica?

How well does Kevzara work for polymyalgia rheumatica?

Kevzara (sarilumab) is an interleukin-6 inhibitor approved by the FDA in 2023 for polymyalgia rheumatica (PMR) in adults who have not responded adequately to corticosteroids alone or cannot tolerate them. Clinical trials showed that 69% of patients reached sustained remission at week 52 compared with 15% on placebo, while steroid doses were reduced to 5 mg or less in 56% of patients versus 18% on placebo.

How does Kevzara compare with standard care?

Standard care relies on long-term corticosteroid use. Patients using Kevzara plus tapered steroids showed sustained remission rates far higher than placebo plus tapered steroids. The drug also cut the total annual steroid exposure by roughly 1,000 mg of prednisone equivalent in treated patients.

What side effects are patients asking about?

Common side effects include injection-site reactions, neutropenia, and elevated liver enzymes. Serious risks center on serious infections, gastrointestinal perforations, and laboratory abnormalities. Patients must be screened for tuberculosis and hepatitis B before starting treatment.

What happens if treatment is interrupted?

Treatment interruptions due to adverse events or patient choice lead to higher relapse rates. Interruption after achievement of sustained remission still leaves 33% of patients zurück into active disease by week 52.

When does Kevzara's patent expire?

Kevzara's composition-of-matter patent expires in 2031 in the U.S. Biosimilars may enter earlier through litigation or settlement.